A Phase II study of Concurrent Chemoradiation plus Durvalumab (MEDI4736) followed by Surgery followed by Adjuvant Durvalumab (MEDI4736) in medically operable patients with surgically resectable Stage III (N2) Non-Small Cell Lung Cancer
The purpose of this study is to estimate the pathological complete response rate at the time of surgery in patients with stage IIIA (N2) NSCLC treated with concurrent Carboplatin/Paclitaxel/Durvalumab plus radiation therapy followed by surgical resection followed by adjuvant Durvalumab.
We are doing this study to find out if the combination of chemotherapy, radiation and FDA approved Durvalumab, followed by surgical resection of your cancer is safe and if it will keep your disease away for a longer period of time. We are also looking at whether adding Durvalumab maintenance after surgical reseaction will provide a longer period of time that your cancer is inactive.
- IRB Number: 1902410868 (LUN17-321)
- Research Study Identifier: TX10373
- Principal Investigator: Greg Durm, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required